References
- Hu J, Liu Y-F, Wu C-F, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009;106:3342–3471.
- Matthews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia:long-term follow up data. J Clin Oncol 2010;28:3866–3871.
- Iland H, Bradstock K, Supple S, et al.;Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and intravenous arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012;120:1570–1580.
- Chen C-J, Chuang Y-C, Lin T-M, et al. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan:high-artesian well water and cancers. Cancer Res 1985;45:5895–5899.
- Guo H-R, Lipsitz S, Hu H, et al. Using ecological data to estimate a regression model for individual data:the association between arsenic in drinking water and incidence of skin cancer. Environ Res 1998;79:82–93.
- Aposhian H, Zakharyan H, Avram M, et al. A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species. Toxicol Appl Pharmacol 2004;198:327–335.
- Au W, Lang BH, Fong BMW, et al. Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia. Leuk Lymphoma 2014;55:1184–1185.
- Smith H. The distribution of antimony, arsenic, copper and zinc in human tissue. Forensic Sci Soc J 1967;7:97–102.
- Pomroy C, Charbonneau R, McCullough R, et al. Human retention studies with 74 As. Toxicol Appl Pharmacol 1980;53:550–556.